Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY22 results · Jul–Sep 2021
Marksans Pharma reported revenue from operations of ₹361.20 crore (up 1.3% from Q2 FY21) and net profit of ₹46.29 crore (down 8.8% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 361.20 | 356.47 | +1.3% | 348.96 | +3.5% |
| Other income | 8.57 | 3.67 | +133.6% | 5.88 | +45.6% |
| Total income | 369.77 | 360.14 | +2.7% | 354.85 | +4.2% |
| Profit before tax | 59.78 | 65.90 | −9.3% | 74.78 | −20.1% |
| Net profit for the period | 46.29 | 50.73 | −8.8% | 62.60 | −26.1% |
| EPS, basic (₹) | 1.11 | 1.21 | −8.3% | 1.51 | −26.5% |
| Net margin (%) | 12.8 | 14.2 | 17.9 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.85 | 137.55 | +22.8% | 147.22 | +14.7% |
| Other income | 8.60 | 12.96 | −33.6% | 13.94 | −38.3% |
| Total income | 177.45 | 150.51 | +17.9% | 161.16 | +10.1% |
| Profit before tax | 37.02 | 31.01 | +19.4% | 34.18 | +8.3% |
| Net profit for the period | 27.60 | 23.53 | +17.3% | 28.91 | −4.5% |
| EPS, basic (₹) | 0.67 | 0.57 | +17.5% | 0.71 | −5.6% |
| Net margin (%) | 16.3 | 17.1 | 19.6 |
Consolidated
- Filed with BSE
- 10 Nov 2021, 15:30 IST
- Board meeting
- 10 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Nov 2021, 15:30 IST
- Board meeting
- 10 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE